Elusys Therapeutics

FDA approves new treatment for inhalation anthrax

Wednesday, March 23, 2016

The FDA has approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

[Read More]